Adults with refractory chronic gout who were treated bi-weekly with Krystexxa (pegloticase) experienced "statistically significant and clinically meaningful improvements" in health-related quality of life (HRQOL), pain, and physical function. Study results were published in the July 2012 issue of the Journal of Rheumatology.
The conclusions were drawn from a pooled analysis of two Phase III studies that included patients treated with 8 mg. Krystexxa every 2 weeks or 4 weeks compared to placebo. Patients receiving monthly Krystexxa also improved in health-related quality of life but not as significantly as those receiving the drug every two weeks.
Related Articles:
- Krystexxa - What You Should Know
- Gout Attack Explained
- Gout - 10 Things You Should Know
- Gout Screening Quiz
Follow Me:
Facebook | Twitter | Message Board | Newsletter
John Steele (iStockphoto)
